A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00087620
Recruitment Status : Terminated
First Posted : July 14, 2004
Last Update Posted : February 3, 2017
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: XELODA [capecitabine] Phase 4

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Actual Study Start Date : September 2004
Actual Primary Completion Date : October 2004
Actual Study Completion Date : October 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have provided written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice
  • Be female and at least 18 years of age. Note: must be 19 years of age if the patient is a resident of the state of Alabama
  • Be ambulatory (outpatient) and have a Karnofsky performance status of more than 70%
  • Have confirmed breast cancer with locally advanced and/or metastases
  • Have at least one site with defined tumor
  • Have met one of the study definitions of primary or nonprimary resistance to an anthracycline-containing therapy

Exclusion Criteria:

  • Pregnant/lactating women
  • Women of childbearing potential with either a positive or no pregnancy test
  • Women of childbearing potential unless using a reliable and appropriate contraceptive method (Postmenopausal women must have not had their period for at least 12 months to be considered of non-childbearing potential)
  • Prior treatment with chemotherapy in the advanced/metastatic setting
  • HER 2/neu positive status without prior treatment with trastuzumab
  • Prior treatment with IV bolus 5-FU, continuous 5-FU infusion, capecitabine or other oral fluoropyrimidines
  • Prior treatment with a taxane if less than 12 months passed from the time of therapy completion to relapse
  • Mitomycin C or nitrosoureas within 6 weeks preceding treatment start
  • Organ allografts requiring immunosuppressive therapy
  • Radiotherapy to the skeleton within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiotherapy
  • Hormonal therapy within 10 days preceding study treatment start
  • Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery
  • Blood transfusions/growth factors to aid hematologic recovery within 2 weeks prior to study treatment start
  • Participation in any investigational drug study within 4 weeks preceding treatment start
  • Prior unanticipated severe reaction to fluoropyrimidine therapy
  • Known hypersensitivity to 5-fluorouracil, taxanes or any of the components of capecitabine
  • Requirement for concurrent use of the antiviral agent sorivudine or chemically related analogues
  • Evidence of CNS metastases
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma
  • Clinically significant (i.e. active) cardiac disease
  • Abnormal laboratory values
  • Severe renal impairment
  • Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
  • Lack of physical integrity of the upper GI tract
  • Life expectancy of less than 3 months
  • Unwilling/unable to comply with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00087620

  Hide Study Locations
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Deer Park, California, United States, 94576
Greenbrae, California, United States, 94904
La Jolla, California, United States, 92037
Los Angeles, California, United States, 90057
Orange, California, United States, 92868
United States, Colorado
Aurora, Colorado, United States, 80010
United States, Florida
Boca Raton, Florida, United States, 33428
Boynton Beach, Florida, United States, 33435
Brooksville, Florida, United States, 34613
Hollywood, Florida, United States, 33021
New Port Richey, Florida, United States, 34652
United States, Georgia
Augusta, Georgia, United States, 30901
Savannah, Georgia, United States, 31405
United States, Illinois
Chicago, Illinois, United States, 60611
Skokie, Illinois, United States, 60077
United States, Iowa
Waterloo, Iowa, United States, 50702
United States, Kansas
Lenexa, Kansas, United States, 66214
United States, Louisiana
Lafayette, Louisiana, United States, 70503
United States, Maine
Scarborough, Maine, United States, 04074
United States, Maryland
Baltimore, Maryland, United States, 21237
Prince Frederick, Maryland, United States, 20678
United States, Michigan
Lansing, Michigan, United States, 48909
United States, Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Nevada
Reno, Nevada, United States, 89502
United States, New York
Rochester, New York, United States, 14642
United States, North Carolina
Durham, North Carolina, United States, 27710
Wilmington, North Carolina, United States, 28401
Winston-salem, North Carolina, United States, 27103
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73112
United States, South Carolina
Florence, South Carolina, United States, 29506
United States, Texas
Corpus Christi, Texas, United States, 78412
Richardson, Texas, United States, 75080
United States, Wisconsin
Milwaukee, Wisconsin, United States, 53215
Racine, Wisconsin, United States, 53405
Sponsors and Collaborators
Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche Identifier: NCT00087620     History of Changes
Other Study ID Numbers: ML17771
First Posted: July 14, 2004    Key Record Dates
Last Update Posted: February 3, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents